Ranbaxy and EPIRUS Switzerland, a wholly-owned subsidiary of Boston-based Epirus Biopharmaceuticals, announced the signing of a licensing agreement for BOW015, a biosimilar version of Infliximab. The product will be introduced in India and other emerging markets. Currently, there is no biosimilar of Infliximab approved in India.
Under the terms of the agreement, EPIRUS will develop and supply the product, and upon regulatory approval Ranbaxy will market the same in India and other emerging markets.
Commenting on the partnership, Sanjeev I Dani, Executive Vice President and Head, Global Strategy, Ranbaxy said, “We are pleased to partner with EPIRUS for Biosimilar Infliximab. We will utilise our strong front-end capabilities in making this product available in India and other parts of the world.”
Amit Munshi, President and Chief Executive Officer, EPIRUS commented, “We are pleased to work with Ranbaxy to register and commercialise this important medicine. Ranbaxy has the right focus and infrastructure in these markets to effectively bring this product to the market.”
EP News Bureau – Mumbai